Validation and comparison of simple noninvasive indexes for predicting liver fibrosis in HIV-HCV-coinfected patients: ANRS CO3 Aquitaine cohort.
Details
Serval ID
serval:BIB_057441FFD0A7
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Validation and comparison of simple noninvasive indexes for predicting liver fibrosis in HIV-HCV-coinfected patients: ANRS CO3 Aquitaine cohort.
Journal
The American journal of gastroenterology
Working group(s)
Groupe d'Epidémiologie Clinique du SIDA en Aquitaine (GECSA)
Contributor(s)
Chêne G., Dabis F., Dupon M., Longy-Boursier M., Morlat P., Pellegrin J.L., Ragnaud J.M., Salamon R., Dabis F., Chêne G., Thiébaut R., Lewden C., Lawson-Ayayi S., Dupon M., Mercié P., Moreau J.F., Morlat P., Pellegrin J.L., Ragnaud J.M., Bernard N., Lacoste D., Malvy D., Neau D., Blaizeau M.J., Decoin M., Delveaux S., Hannapier C., Labarrére S., Lavignolle-Aurillac V., Uwamaliya-Nziyumvira B., Palmer G., Touchard D., Winnock M., Balestre E., Alioum A., Jacqmin-Gadda H., Thiébaut R., Morlat P., Bernard N., Bonarek M., Bonnet F., Gellie P., Lacoste D., Lacombe K., Dupon M., Dauchy F., Dutronc H., Lafarie S., Longy-Boursier M., Mercié P., Malvy D., Pistonne T., Thibaut P., Ragnaud J.M., Chambon D., De La Taille C., Cazorla C., Galperine T., Neau D., Ochoa A., Pellegrin J.L., Viallard J.F., Caubet O., Lazaro E., Nouts C., Couzigou P., Castera L., Fleury H., Lafon M.F., Masquelier B., Pellegrin I., Breilh D., Moreau J.F., Blanco P., Loste P., Caunègre L., Bonnal F., Farbos S., Gemain M.C., Ceccaldi J., Tchamgoué S., De Witte S.
ISSN
1572-0241 (Electronic)
ISSN-L
0002-9270
Publication state
Published
Issued date
08/2008
Peer-reviewed
Oui
Volume
103
Number
8
Pages
1973-1980
Language
english
Notes
Publication types: Comparative Study ; Journal Article ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Publication Status: ppublish
Abstract
Although an increasing number of noninvasive fibrosis markers are available in HCV-monoinfected patients, data on the performance of these tests in HIV-HCV-coinfected patients are lacking.
To assess the diagnostic performance for predicting hepatic fibrosis stage of four simple and inexpensive noninvasive indexes (FIB-4, APRI, Forns, and platelet count) in HIV-HCV-coinfected patients.
Two hundred consecutive HIV-HCV-coinfected patients from the ANRS-CO3 Aquitaine cohort who underwent liver biopsy were studied. Fibrosis stage was assessed according to Metavir scoring system by a single pathologist unaware of the data of the patients. Diagnostic performances were assessed by measuring the areas under the receiver operating characteristic curves (AUROC) and the percentage of patients correctly identified (PCI).
For predicting significant fibrosis (F > or = 2), APRI, Forns index, and FIB-4 had AUROCS of 0.77, 0.75, and 0.79, with 39%, 25%, and 70% of PCI, respectively. For predicting severe fibrosis (F > or = 3), FIB-4 had AUROC of 0.77 with 56% of PCI. For predicting cirrhosis (F4), FIB-4, APRI, and platelet count had AUROCs of 0.80, 0.79, and 0.78, with 59%, 60%, and 76% of PCI, respectively. Overall, diagnostic performances of the different indexes did not differ significantly for both significant fibrosis and cirrhosis.
The use of these noninvasive indexes could save liver biopsies in up to 56-76% of cases for the prediction of severe fibrosis-cirrhosis. However, given the high percentage of misclassified cases for significant fibrosis, such indexes do not appear currently suitable for use in clinical practice in HIV-HCV-coinfected patients.
To assess the diagnostic performance for predicting hepatic fibrosis stage of four simple and inexpensive noninvasive indexes (FIB-4, APRI, Forns, and platelet count) in HIV-HCV-coinfected patients.
Two hundred consecutive HIV-HCV-coinfected patients from the ANRS-CO3 Aquitaine cohort who underwent liver biopsy were studied. Fibrosis stage was assessed according to Metavir scoring system by a single pathologist unaware of the data of the patients. Diagnostic performances were assessed by measuring the areas under the receiver operating characteristic curves (AUROC) and the percentage of patients correctly identified (PCI).
For predicting significant fibrosis (F > or = 2), APRI, Forns index, and FIB-4 had AUROCS of 0.77, 0.75, and 0.79, with 39%, 25%, and 70% of PCI, respectively. For predicting severe fibrosis (F > or = 3), FIB-4 had AUROC of 0.77 with 56% of PCI. For predicting cirrhosis (F4), FIB-4, APRI, and platelet count had AUROCs of 0.80, 0.79, and 0.78, with 59%, 60%, and 76% of PCI, respectively. Overall, diagnostic performances of the different indexes did not differ significantly for both significant fibrosis and cirrhosis.
The use of these noninvasive indexes could save liver biopsies in up to 56-76% of cases for the prediction of severe fibrosis-cirrhosis. However, given the high percentage of misclassified cases for significant fibrosis, such indexes do not appear currently suitable for use in clinical practice in HIV-HCV-coinfected patients.
Keywords
Adult, Cohort Studies, Female, HIV Infections/complications, Health Status Indicators, Hepatitis C, Chronic/blood, Hepatitis C, Chronic/complications, Humans, Liver Cirrhosis/diagnosis, Liver Cirrhosis/virology, Liver Function Tests, Male, Middle Aged, Platelet Count, Predictive Value of Tests, Reproducibility of Results, Retrospective Studies
Pubmed
Web of science
Create date
30/01/2023 19:26
Last modification date
31/01/2023 6:55
Usage data
